IN2014CN02971A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN02971A IN2014CN02971A IN2971CHN2014A IN2014CN02971A IN 2014CN02971 A IN2014CN02971 A IN 2014CN02971A IN 2971CHN2014 A IN2971CHN2014 A IN 2971CHN2014A IN 2014CN02971 A IN2014CN02971 A IN 2014CN02971A
- Authority
- IN
- India
- Prior art keywords
- formula
- compound
- alkyl
- halo
- orn
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 abstract 2
- 150000001412 amines Chemical class 0.000 abstract 1
- 230000008878 coupling Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- FDKLLWKMYAMLIF-UHFFFAOYSA-N cyclopropane-1,1-dicarboxylic acid Chemical compound OC(=O)C1(C(O)=O)CC1 FDKLLWKMYAMLIF-UHFFFAOYSA-N 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003880 polar aprotic solvent Substances 0.000 abstract 1
- 150000003512 tertiary amines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/58—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/59—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161549312P | 2011-10-20 | 2011-10-20 | |
| PCT/US2012/061320 WO2013059788A1 (en) | 2011-10-20 | 2012-10-22 | Process for preparing quinoline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN02971A true IN2014CN02971A (cs) | 2015-07-03 |
Family
ID=47146705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2971CHN2014 IN2014CN02971A (cs) | 2011-10-20 | 2012-10-22 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US9365516B2 (cs) |
| EP (1) | EP2768796B1 (cs) |
| JP (2) | JP6208140B2 (cs) |
| KR (1) | KR102075371B1 (cs) |
| CN (2) | CN104395284A (cs) |
| AR (1) | AR088483A1 (cs) |
| AU (2) | AU2012325768B2 (cs) |
| BR (1) | BR112014009302B1 (cs) |
| CA (1) | CA2852771C (cs) |
| DK (1) | DK2768796T3 (cs) |
| EA (1) | EA031485B1 (cs) |
| ES (1) | ES2765013T3 (cs) |
| GE (1) | GEP20207110B (cs) |
| HU (1) | HUE048023T2 (cs) |
| IL (1) | IL232139A (cs) |
| IN (1) | IN2014CN02971A (cs) |
| MX (1) | MX343288B (cs) |
| PL (1) | PL2768796T3 (cs) |
| PT (1) | PT2768796T (cs) |
| TW (2) | TWI619694B (cs) |
| UA (1) | UA116876C2 (cs) |
| WO (1) | WO2013059788A1 (cs) |
| ZA (1) | ZA201402579B (cs) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9724342B2 (en) | 2010-07-16 | 2017-08-08 | Exelixis, Inc. | C-met modulator pharmaceutical compositions |
| SI2621481T2 (sl) | 2010-09-27 | 2023-02-28 | Exelixis, Inc., | Dvojni inhibitorji MET in VEGF za zdravljenje proti kastraciji odpornega raka prostate in osteoblastnih kostnih metastaz |
| EP2673262B1 (en) | 2011-02-10 | 2021-11-03 | Exelixis, Inc. | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
| US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
| UA115527C2 (uk) | 2011-05-02 | 2017-11-27 | Екселіксіс, Інк. | Застосування n-(4-{[6,7-бic(мeтилoкcи)xiнoлiн-4-iл]oкcи}фeнiл)-n'-(4-фтopфeнiл)циклoпpoпaн-1,1-дикapбoкcaмiду для лікування нирково-клітинної карциноми (варіанти) |
| CA2848512A1 (en) | 2011-09-22 | 2013-03-28 | Exelixis, Inc. | Method for treating osteoporosis |
| BR112014009302B1 (pt) * | 2011-10-20 | 2020-04-28 | Exelis Inc Us/Us | processo para preparar derivados de quinolina |
| US9861624B2 (en) | 2012-05-02 | 2018-01-09 | Exelixis, Inc. | Method of treating cancer |
| WO2014145715A1 (en) | 2013-03-15 | 2014-09-18 | Exelixis, Inc. | Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide |
| WO2014165786A1 (en) | 2013-04-04 | 2014-10-09 | Exelixis, Inc. | Cabozantinib dosage form and use in the treatment of cancer |
| CN104649969B (zh) * | 2013-11-22 | 2019-02-12 | 广东东阳光药业有限公司 | 一种替尼类药物的盐及其制备方法 |
| CA3181899A1 (en) | 2014-02-14 | 2015-08-20 | Exelixis, Inc. | Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
| WO2015142928A1 (en) | 2014-03-17 | 2015-09-24 | Exelixis, Inc. | Dosing of cabozantinib formulations |
| CN104788372B (zh) * | 2014-07-25 | 2018-01-30 | 上海圣考医药科技有限公司 | 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体 |
| EP3174854B1 (en) | 2014-07-31 | 2022-08-24 | Exelixis, Inc. | Method of preparing fluorine-18 labeled cabozantinib and its analogs |
| EP3177311B1 (en) | 2014-08-05 | 2024-10-30 | Exelixis, Inc. | Drug combinations of cabozantinib with proteasome inhibitor to treat multiple myeloma |
| EP3345894B1 (en) * | 2015-09-02 | 2021-12-29 | Chen, Kuenfeng | Compound having protein tyrosine phosphatase shp-1 agonist activity |
| WO2017181187A1 (en) | 2016-04-15 | 2017-10-19 | Exelixis, Inc. | Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate |
| CN109836382B (zh) * | 2017-11-29 | 2021-11-05 | 江苏豪森药业集团有限公司 | 苹果酸卡博替尼及其中间体的制备方法 |
| EP3743070B1 (en) | 2018-01-26 | 2025-07-23 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| CN115192540A (zh) | 2018-06-15 | 2022-10-18 | 汉达癌症医药责任有限公司 | 激酶抑制剂的盐类及其组合物 |
| CN112142619B (zh) * | 2020-10-20 | 2023-01-10 | 浙江工业大学 | 一种1,1-环丙烷二羧酸酰胺类化合物及其制备方法和应用 |
| JP2024513179A (ja) * | 2021-03-24 | 2024-03-22 | バイオコン・リミテッド | カボザンチニブの調製のためのプロセス |
| AU2023384196A1 (en) * | 2022-11-25 | 2025-06-12 | Msn Laboratories Private Limited, R&D Center | Crystalline forms of n-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide fumarate and process for its preparation |
| WO2024163400A1 (en) | 2023-01-31 | 2024-08-08 | Handa Oncology, Llc | Improved cabozantinib compositions and methods of use |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2213661E (pt) | 2003-09-26 | 2011-12-15 | Exelixis Inc | Moduladores de c-met e métodos de uso |
| CA2572331A1 (en) | 2004-07-02 | 2006-02-09 | Exelixis, Inc. | C-met modulators and method of use |
| US20080161305A1 (en) | 2005-04-06 | 2008-07-03 | Exelixis, Inc. | C-Met Modulators and Methods of Use |
| EP2101759B1 (en) | 2006-12-14 | 2018-10-10 | Exelixis, Inc. | Methods of using mek inhibitors |
| UY31800A (es) | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
| WO2009136663A1 (en) * | 2008-05-08 | 2009-11-12 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivatives and use thereof |
| TW201035017A (en) * | 2008-09-26 | 2010-10-01 | Smithkline Beecham Corp | Preparation of a quinolinyloxydiphenylcyclopropanedicarboxamide |
| EA019247B1 (ru) | 2008-11-13 | 2014-02-28 | Экселиксис, Инк. | Способы получения хинолиновых производных |
| WO2010065838A1 (en) | 2008-12-04 | 2010-06-10 | Exelixis, Inc. | Methods of preparing quinoline derivatives |
| PL2387563T5 (pl) | 2009-01-16 | 2023-03-13 | Exelixis, Inc. | Sól jabłczanowa N-(4-{[6,7-bis(metyloksy)chinolin-4-ylo]oksy}fenylo-N′-(4-fluorofenylo)cykloproano-1,1-dikarboksyamidu oraz jej krystaliczne postaci do leczenia raka |
| CA2768370A1 (en) | 2009-07-17 | 2011-01-20 | Exelixis, Inc. | Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| CA2792852A1 (en) | 2010-03-12 | 2011-09-15 | Exelixis, Inc. | Hydrated crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| US20120070368A1 (en) | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
| US9724342B2 (en) | 2010-07-16 | 2017-08-08 | Exelixis, Inc. | C-met modulator pharmaceutical compositions |
| WO2012009723A1 (en) | 2010-07-16 | 2012-01-19 | Exelixis, Inc. | C-met modulator pharmaceutical compositions |
| WO2012044574A1 (en) | 2010-09-27 | 2012-04-05 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
| SI2621481T2 (sl) | 2010-09-27 | 2023-02-28 | Exelixis, Inc., | Dvojni inhibitorji MET in VEGF za zdravljenje proti kastraciji odpornega raka prostate in osteoblastnih kostnih metastaz |
| EP2621483A1 (en) | 2010-09-27 | 2013-08-07 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
| JP2013543011A (ja) | 2010-11-22 | 2013-11-28 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド | 癌の治療法 |
| EP2673262B1 (en) | 2011-02-10 | 2021-11-03 | Exelixis, Inc. | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
| US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
| UA115527C2 (uk) | 2011-05-02 | 2017-11-27 | Екселіксіс, Інк. | Застосування n-(4-{[6,7-бic(мeтилoкcи)xiнoлiн-4-iл]oкcи}фeнiл)-n'-(4-фтopфeнiл)циклoпpoпaн-1,1-дикapбoкcaмiду для лікування нирково-клітинної карциноми (варіанти) |
| TW201306842A (zh) | 2011-06-15 | 2013-02-16 | Exelixis Inc | 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法 |
| CA2848512A1 (en) | 2011-09-22 | 2013-03-28 | Exelixis, Inc. | Method for treating osteoporosis |
| BR112014009302B1 (pt) | 2011-10-20 | 2020-04-28 | Exelis Inc Us/Us | processo para preparar derivados de quinolina |
| TW201818937A (zh) | 2011-11-08 | 2018-06-01 | 美商艾克塞里克斯公司 | 治療癌症之方法 |
| US9861624B2 (en) | 2012-05-02 | 2018-01-09 | Exelixis, Inc. | Method of treating cancer |
| CN104703600A (zh) | 2012-09-07 | 2015-06-10 | 埃克塞里艾克西斯公司 | 用于治疗肺腺癌的met、vegfr和ret的抑制剂 |
-
2012
- 2012-10-22 BR BR112014009302A patent/BR112014009302B1/pt active IP Right Grant
- 2012-10-22 CA CA2852771A patent/CA2852771C/en active Active
- 2012-10-22 DK DK12783763.1T patent/DK2768796T3/da active
- 2012-10-22 ES ES12783763T patent/ES2765013T3/es active Active
- 2012-10-22 AU AU2012325768A patent/AU2012325768B2/en active Active
- 2012-10-22 AR ARP120103944 patent/AR088483A1/es not_active Application Discontinuation
- 2012-10-22 US US14/353,251 patent/US9365516B2/en active Active
- 2012-10-22 GE GEAP201213471A patent/GEP20207110B/en unknown
- 2012-10-22 TW TW101139005A patent/TWI619694B/zh active
- 2012-10-22 KR KR1020147012435A patent/KR102075371B1/ko active Active
- 2012-10-22 HU HUE12783763A patent/HUE048023T2/hu unknown
- 2012-10-22 PL PL12783763T patent/PL2768796T3/pl unknown
- 2012-10-22 CN CN201280054241.3A patent/CN104395284A/zh active Pending
- 2012-10-22 IN IN2971CHN2014 patent/IN2014CN02971A/en unknown
- 2012-10-22 JP JP2014537359A patent/JP6208140B2/ja active Active
- 2012-10-22 TW TW106121791A patent/TWI642650B/zh active
- 2012-10-22 CN CN201910783833.2A patent/CN110511158A/zh active Pending
- 2012-10-22 MX MX2014004583A patent/MX343288B/es active IP Right Grant
- 2012-10-22 WO PCT/US2012/061320 patent/WO2013059788A1/en not_active Ceased
- 2012-10-22 PT PT127837631T patent/PT2768796T/pt unknown
- 2012-10-22 EA EA201490831A patent/EA031485B1/ru unknown
- 2012-10-22 UA UAA201405355A patent/UA116876C2/uk unknown
- 2012-10-22 EP EP12783763.1A patent/EP2768796B1/en active Active
-
2014
- 2014-04-09 ZA ZA2014/02579A patent/ZA201402579B/en unknown
- 2014-04-22 IL IL232139A patent/IL232139A/en active IP Right Grant
-
2016
- 2016-04-20 US US15/133,708 patent/US9969692B2/en active Active
-
2017
- 2017-06-07 JP JP2017112355A patent/JP2017222648A/ja active Pending
- 2017-11-06 AU AU2017254982A patent/AU2017254982A1/en not_active Abandoned
-
2018
- 2018-04-17 US US15/955,246 patent/US20180230100A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN02971A (cs) | ||
| MX2014006992A (es) | Disales de acido malonico y metodo para preparar dihaluros de malonilo. | |
| AU2012248061C1 (en) | Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof | |
| PH12016502334B1 (en) | Method for producing fused heterocyclic compound | |
| IN2014MN01521A (cs) | ||
| EP2681204A4 (en) | SYNTHESIS OF INTERMEDIATE PRODUCTS FOR TREPROSTINE PRODUCTION | |
| IN2014DN00144A (cs) | ||
| NZ601805A (en) | Method for preparing tetrazole methanesulfonic acid salts, and novel compound used in same | |
| IN2014MN00976A (cs) | ||
| MY160511A (en) | Synthesis of rare earth metal extractant | |
| IN2015DN00665A (cs) | ||
| IN2014CN02346A (cs) | ||
| WO2011102640A3 (en) | Method for preparing sitagliptin and amine salt intermediates used therein | |
| MX2012001722A (es) | Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable. | |
| IN2012DN00361A (cs) | ||
| MX2013008595A (es) | Procedimiento mejorado para la preparacion de 2,2-difluoroetilamina. | |
| UA113067C2 (xx) | Спосіб одержання хінолінкарбонової кислоти | |
| IN2014CN04123A (cs) | ||
| UA111329C2 (uk) | Спосіб синтезу івабрадину і його адитивних солей з фармацевтично прийнятною кислотою | |
| BR112013018809A8 (pt) | Processo para produção de derivados de ácido amidocarboxílico aromático | |
| MX345768B (es) | Procedimiento para la preparación de 2,2-dufluoroetilamina partiendo de un compuesto de bencilamina. | |
| NZ709587A (en) | Method for preparing cyclopropane derivatives | |
| GEP20156369B (en) | New process for synthesis of ivabradine and addition salts therewith pharmaceutically acceptable acid | |
| MX352295B (es) | Compuestos de fenilo sustituidos. | |
| IN2014DN10440A (cs) |